Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688

Translational Psychiatry

Volumn 5, Issue , 2015, Pages

  DeLorenzo, C ^a,b   Sovago, J ^c   Gardus, J ^b   Xu, J ^d   Yang, J ^b   Behrje, R ^c   Kumar, J S D ^a   Devanand, D P ^a   Pelton, G H ^a   Mathis, C A ^e   Mason, N S ^e   Gomez Mancilla, B ^c   Aizenstein, H ^e   Mann, J J ^a   Parsey, R V ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Stony Brook University   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABP 688 C 11; METABOTROPIC RECEPTOR 5; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3-(6-METHYLPYRIDIN-2-YLETHYNYL)CYCLOHEX-2-ENONE-O-METHYLOXIME; CARBON; OXIME; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR DEPRESSION; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POTENTIAL DIFFERENCE; PROTEIN BINDING; BRAIN; METABOLISM;

AGED; BRAIN; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIMES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84948752067     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.189     Document Type: Article

References (62)

1. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 2006; 113: 372-387.
2. Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging 2010; 27: 625-640.
3. Fiske A, Wetherell JL, Gatz M. Depression in older adults. Annu Rev Clin Psychol 2009; 5: 363-389.
4. Brodaty H, Luscombe G, Parker G, Wilhelm K, Hickie I, Austin MP et al. Early and late onset depression in old age: different aetiologies, same phenomenology. J Affect Disord 2001; 66: 225-236.
5. Korten NC, Comijs HC, Lamers F, Penninx BW. Early and late onset depression in young and middle aged adults: differential symptomatology, characteristics and risk factors J Affect Disord 2012; 138: 259-267.
6. Lebedeva A, Westman E, Lebedev AV, Li X, Winblad B, Simmons A et al. Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2014; 85: 930-935.
7. Spooren W, Lesage A, Lavreysen H, Gasparini F, Steckler T. Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Topics Behav Neurosci 2010; 2: 391-413.
8. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R et al. Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132: 1423-1430.
9. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625.
10. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17: 172-179.
11. Palucha A, Branski P, Szewczyk B, Wieronska JM, Klak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005; 81: 901-906.
12. Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006; 319: 254-259.
13. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011; 168: 727-734.
14. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C et al. In vivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 2014; 77: 266-275.
15. Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol Psychiatry 2013; 73: 161-168.
16. Menard C, Quirion R. Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways. PLoS One 2012; 7: e28666.
17. Domenici MR, Pintor A, Potenza RL, Gaudi S, Gro MC, Passarelli F et al. Metabotropic glutamate receptor 5 (mGluR5)-mediated phosphoinositide hydrolysis and NMDA-potentiating effects are blunted in the striatum of aged rats: a possible additional mechanism in striatal senescence. Eur J Neurosci 2003; 17: 2047-2055.
18. Tsamis KI, Mytilinaios DG, Njau SN, Baloyannis SJ. Glutamate receptors in human caudate nucleus in normal aging and Alzheimer's disease. Curr Alzheim Res 2013; 10: 469-475.
19. DuBois JM, Rousset OG, Rowley J, Porras-Betancourt M, Reader AJ, Labbe A et al. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [C]ABP688 PET. Eur J Nucl Med Mol Imaging 2015.
20. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47: 698-705.
21. Elmenhorst D, Minuzzi L, Aliaga A, Rowley J, Massarweh G, Diksic M et al. In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C] ABP688. J Cereb Blood Flow Metab 2010; 30: 1538-1549.
22. DeLorenzo C, Milak MS, Brennan KG, Kumar JS, Mann JJ, Parsey RV. In vivo positron emission tomography imaging with [(11)C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging 2011; 38: 1083-1094.
23. DeLorenzo C, Kumar JS, Mann JJ, Parsey RV. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab 2011; 31: 2169-2180.
24. Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med 2007; 48: 1207-1215.
25. Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 1998; 8: 426-440.
26. Zanotti-Fregonara P, Hines CS, Zoghbi SS, Liow JS, Zhang Y, Pike VW et al. Population-based input function and image-derived input function for [(11)C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder. Neuroimage 2012; 63: 1532-1541.
27. Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 2012; 39: 544-547.
28. Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ et al. A semipopulation input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun 2012; 33: 881-888.
29. Tsuchida T, Sadato N, Yonekura Y, Nakamura S, Takahashi N, Sugimoto K et al. Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. J Nucl Med 1999; 40: 1441-1445.
30. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
31. Ogden RT, Tarpey T. Estimation in regression models with externally estimated parameters. Biostatistics 2006; 7: 115-129.
32. Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol2007; 34: 1009-1017.
33. Burger C, Deschwanden A, Ametamey S, Johayem A, Mancosu B, Wyss M et al. Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl Med Biol 2010; 37: 845-851.
34. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
35. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Map 1999; 7: 254-266.
36. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med iMage Anal 2008; 12: 26-41.
37. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B et al. Multiple MPEP administrations evoke anxiolytic-and antidepressant-like effects in rats. Neuropharmacology 2002; 43: 181-187.
38. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 2005; 179: 207-217.
39. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C et al. In vivo ketamine-induced changes in [(1)(1)C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 2015; 77: 266-275.
40. Miyake N, Skinbjerg M, Easwaramoorthy B, Kumar D, Girgis RR, Xu X et al. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol psychiatry 2011; 69: 822-824.
41. E RZ, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L et al. Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone. J Cereb Blood Flow Metab 2015; 35: 1169-1174.
42. Wyckhuys T, Verhaeghe J, Wyffels L, Langlois X, Schmidt M, Stroobants S et al. N-acetylcysteine-and MK-801-induced changes in glutamate levels do not affect in vivo binding of metabotropic glutamate 5 receptor radioligand 11C-ABP688 in rat brain. J Nucl Med 2013; 54: 1954-1961.
43. Kosten L, Thomas D, Verhaeghe J, Wyffels L, Stroobants S, Staelens S. Acute Ketamine Infusion in Rat Does Not Affect In Vivo [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Brain. BrainPET, Vancouver, BC, USA: 2015.
44. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012; 62: 63-77.
45. Treyer V, Streffer J, Ametamey SM, Bettio A, Blauenstein P, Schmidt M et al. Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. Eur J Nucl Med Mol Imaging 2008; 35: 766-770.
46. Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci USA 2013; 110: 737-742.
47. Akkus F, Terbeck S, Ametamey SM, Rufer M, Treyer V, Burger C et al. Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2014; 17: 1915-1922.
48. DeLorenzo C, Milak MS, Brennan KG, Kumar JS, Mann JJ, Parsey RV. In vivo positron emission tomography imaging with [(1)(1)C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging 2011; 38: 1083-1094.
49. Hesselgrave N, Parsey RV. Imaging the serotonin 1A receptor using [11C] WAY100635 in healthy controls and major depression. Philos Trans R Soc Lond B 2013; 368: 20120004.
50. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993; 13: 24-42.
51. Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS. Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry 2015; 20: 1057-1068.
52. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther2007; 115: 116-147.
53. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatr Clin Neurosci 2013; 263: 367-377.
54. Arsenault D, Zhu A, Gong C, Kil KE, Kura S, Choi JK et al. Hypo-anxious phenotype of adolescent offspring prenatally exposed to LPS is associated with reduced mGluR5 expression in hippocampus. Open J Med Psychol 2014; 3: 202-211.
55. Kumar J, Hapidin H, Bee YT, Ismail Z. Effects of the mGluR5 antagonist MPEP on ethanol withdrawal induced anxiety-like syndrome in rats. Behav Brain Funct 2013; 9: 43.
56. Page ME, Szeliga P, Gasparini F, Cryan JF. Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology 2005; 179: 240-246.
57. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982; 2: 129-133.
58. Leuzy A, Zimmer ER, Dubois J, Pruessner J, Cooperman C, Soucy JP et al. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. Brain Struct Funct 2015; 1-16.
59. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013; 79: 887-902.
60. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010; 66: 739-754.
61. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844.
62. Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 2008; 22: 261-268.